التداخل بين بوسنتان وتريبروستينيل

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil.

Co-administration of the CYP2C8 enzyme inducer, rifampin, decreases exposure to treprostinil.

Bosentan In a human pharmacokinetic study conducted with bosentan (250 mg/day) and an oral formulation of treprostinil (treprostinil diolamine), no pharmacokinetic interactions between treprostinil and bosentan were observed.